USD 0.0
(0.0%)
Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | -10.32 Million |
Net Income | - | - | - | - | - | -21.52 Million |
Depreciation & Amortization | - | - | - | - | - | 48 Thousand |
Deferred income taxes | - | - | - | - | - | 12.61 Million |
Stock-based compensation | - | - | - | - | - | 190 Thousand |
Change in working capital | - | - | - | - | - | 818 Thousand |
Other non-cash items | - | - | - | - | - | 10.14 Million |
Investing Cash Flow | - | - | - | - | - | -5.08 Million |
Investments in PPE | - | - | - | - | - | -9.11 Million |
Acquisitions | - | - | - | - | - | 4.1 Million |
Investment purchases | - | - | - | - | - | - |
Sales/Maturities of investments | - | - | - | - | - | - |
Other Investing Activities | - | - | - | - | - | -75 Thousand |
Financing Cash Flow | - | - | - | - | - | 7.54 Million |
Debt repayment | - | - | - | - | - | - |
Dividends payments | - | - | - | - | - | - |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | 5.66 Million |
Other Financing Activities | - | - | - | - | - | 1.87 Million |
Accounts receivables | - | - | - | - | - | - |
Accounts payables | - | - | - | - | - | -337 Thousand |
Inventory | - | - | - | - | - | - |
Other working capital | - | - | - | - | - | 1.15 Million |
Cash at beginning of period | - | - | - | - | - | 10.32 Million |
Cash at end of period | - | - | - | - | - | 2.45 Million |
Capital Expenditure | - | - | - | - | - | -9.11 Million |
Effect of forex changes on cash | - | - | - | - | - | - |
Net cash flow / Change in cash | - | - | - | - | - | -7.87 Million |
Free Cash Flow | - | - | - | - | - | -19.43 Million |
Breakdown | 2022 FY | 2021 FY | 2020 FY | 2019 FY | 2018 FY | 2016 FY |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | - | - | - | - | - | -21.52 Million |
Depreciation & Amortization | - | - | - | - | - | 48 Thousand |
Deferred income taxes | - | - | - | - | - | 12.61 Million |
Stock-based compensation | - | - | - | - | - | 190 Thousand |
Change in working capital | - | - | - | - | - | 818 Thousand |
Other non-cash items | - | - | - | - | - | 10.14 Million |
Investing Cash Flow | - | - | - | - | - | -5.08 Million |
Investments in PPE | - | - | - | - | - | -9.11 Million |
Acquisitions | - | - | - | - | - | 4.1 Million |
Investment purchases | - | - | - | - | - | - |
Sales/Maturities of investments | - | - | - | - | - | - |
Other Investing Activities | - | - | - | - | - | -75 Thousand |
Financing Cash Flow | - | - | - | - | - | 7.54 Million |
Debt repayment | - | - | - | - | - | - |
Dividends payments | - | - | - | - | - | - |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | 5.66 Million |
Other Financing Activities | - | - | - | - | - | 1.87 Million |
Accounts receivables | - | - | - | - | - | - |
Accounts payables | - | - | - | - | - | -337 Thousand |
Inventory | - | - | - | - | - | - |
Other working capital | - | - | - | - | - | 1.15 Million |
Cash at beginning of period | - | - | - | - | - | 10.32 Million |
Cash at end of period | - | - | - | - | - | 2.45 Million |
Capital Expenditure | - | - | - | - | - | -9.11 Million |
Effect of forex changes on cash | - | - | - | - | - | - |
Net cash flow / Change in cash | - | - | - | - | - | -7.87 Million |
Free Cash Flow | - | - | - | - | - | -19.43 Million |
FSTR
TOP-R
BALPHARMA
0I8F
000810
9225